Formycon AG (FRA:FYB)
25.30
+0.30 (1.20%)
At close: Jan 6, 2026
Formycon AG Employees
Formycon AG had 250 employees as of December 31, 2024. The number of employees increased by 12 or 5.04% compared to the previous year.
Employees
250
Change (1Y)
12
Growth (1Y)
5.04%
Revenue / Employee
€192,296
Profits / Employee
€660,688
Market Cap
455.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 250 | 12 | 5.04% |
| Dec 31, 2023 | 238 | 33 | 16.10% |
| Dec 31, 2022 | 205 | 34 | 19.88% |
| Dec 31, 2021 | 171 | 40 | 30.53% |
| Dec 31, 2020 | 131 | 18 | 15.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Formycon AG News
- 19 days ago - EQS-News: FDA approves another interchangeable Ranibizumab Biosimilar, Nufymco – Strengthening US Presence with Zydus as Commercialization Partner - Wallstreet:Online
- 4 weeks ago - Formycon AG: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Finanz Nachrichten
- 4 weeks ago - Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda (Pembrolizumab), in the U.S. and Canada - Wallstreet:Online
- 5 weeks ago - Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Finanz Nachrichten
- 5 weeks ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq
- 5 weeks ago - EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Wallstreet:Online
- 6 weeks ago - EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy - Wallstreet:Online